EDSA Edesa Biotech Inc
Company Analysis
Latest News
Edesa Biotech Launches Public Offering, Funding Research and Development
Edesa Biotech commenced an underwritten public offering on August 19, 2026. The offering includes common shares, pre-funded warrants, and accompanying common...
🔴 Edesa Biotech is trading 22.26% down in after-hours trading — no clear catalyst identified
Edesa Biotech is trading 22.26% down at $4.47 after falling sharply from its August 19 regular-session close; no reliable company-specific announcement or...
🟢 Edesa Biotech rises 5.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Edesa Biotech is trading 5% up today in pre-market
Edesa Biotech is trading at $6.00 (+5.03%) in the August 19, 2026 pre-market session, with no clear company-specific catalyst identified. - Recent fiscal...
🟢 Edesa Biotech is trading 7.7% up in after-hours trading without a clearly identified catalyst
Edesa Biotech is trading at $6.15, up 7.71% after-hours on August 18, 2026, without a clearly identified company-specific catalyst. - The August 13 earnings...
🟢 Edesa Biotech is trading 10.47% up today after fiscal third-quarter update and EB06 trial progress
Edesa Biotech is trading 10.47% up at $5.91 after investors responded to its August 13 fiscal third-quarter update. - Reported a $5.4 million quarterly net...
🟢 Edesa Biotech is trading 9.44% up today — no new company-specific announcement identified
Edesa Biotech is trading at $5.86 (+9.44%) with no new company-specific announcement dated August 17, 2026 identified. - The latest reported update, on August...
🟢 Edesa Biotech is trading 10% up in after-hours trading after Phase 2 EB06 vitiligo-site activation
Edesa Biotech is trading 10.28% up now at $5.90 in after-hours trading after closing at $5.35 on August 14, 2026, as the clinical milestone appears to outweigh...
🟢 Edesa Biotech is trading 7.48% up in after-hours trading as EB06 vitiligo study nears recruitment
Edesa Biotech is trading at $5.75 (+7.48%) in after-hours trading, despite an earnings miss, as investors may be responding to completed preparations and...
🟢 Edesa Biotech is trading 5.89% up today after EB06 Phase 2 preparations and site activation
Edesa Biotech is trading 5.89% up now at $5.75 after August 13, 2026 fiscal third-quarter results highlighted completed Phase 2 EB06 preparations and initial...
🟢 Edesa Biotech is trading 5% up today in pre-market after fiscal third-quarter report and EB06 site activation
Edesa Biotech is trading 5.16% up at $5.71 after its August 13, 2026 fiscal third-quarter report and EB06 trial progress. - Reported a $5.4 million net loss,...
Edesa Biotech Shrugs Off an Earnings Miss to Rally on a Vitiligo Trial Milestone — But Can $10 Million in Cash Fund the Bet?
Shares shifted as Edesa Biotech (EDSA) jumped 8.3% to $5.88 in after-hours trading on August 13, despite posting a wider-than-expected quarterly loss....
🟢 Edesa Biotech is trading 8.3% up in after-hours trading after EB06 Phase 2 site activation
Edesa Biotech is trading 8.29% up at $5.88, with the after-hours gain appearing driven by completed preparations and site activation for the Phase 2 EB06...
Edesa Biotech third quarter 2026 loss of $0.60 per share misses analyst estimates
Edesa Biotech reported a net loss of $5.4 million for the third quarter of 2026, widening significantly from the prior year as the company ramped up clinical...
Edesa Biotech Inc Q2 2026 Earnings Preview: What Analysts Expect on August 14, 2026
Edesa Biotech Inc is expected to report zero revenue and a consensus EPS loss of -$0.44 for the quarter ending June 30, 2026, with its $5.72 stock price...
🔴 Edesa Biotech is trading 8.33% down in after-hours trading with no clear company-specific catalyst
Edesa Biotech is trading at $5.06, down 8.33%, with no clear Edesa Biotech-specific announcement identified for August 11, 2026. - Its official news page was...
🟢 Edesa Biotech is trading 5.59% up today after argenx agreed to acquire Forte Biosciences
Edesa Biotech is trading at $5.53, up +5.59% on August 11, 2026, as investors respond positively to immunology-sector deal activity. - argenx agreed to...
🟢 Edesa Biotech is trading 7.06% up in pre-market after argenx's $2.2 billion Forte acquisition
Edesa Biotech is trading 7.06% up in pre-market at $5.61 after positive immunology-sector sentiment linked to argenx’s approximately $2.2 billion acquisition...
🟢 Edesa Biotech is trading 6.87% up in after-hours trading after argenx’s $2.2 billion Forte acquisition
Edesa Biotech is trading 6.87% up now at $5.60 after positive immunology-sector sentiment linked to argenx’s agreement to acquire Forte Biosciences for...
🟢 Edesa Biotech is trading 5.69% up today after argenx’s $2.2 billion Forte acquisition
Edesa Biotech is trading 5.69% up now at $5.57, continuing positive biotech-sector sentiment linked to argenx’s $2.2 billion acquisition of Forte...